When the U.S. Food and Drug Administration invites industry leaders to participate in one of its Patient-Focused Drug Development meetings, the conversation extends well beyond a single company or technology.
These meetings are designed to bring together patients, caregivers, physicians, researchers, and medical product developers to discuss something that has become increasingly important in healthcare: what meaningful treatment actually looks like from the patient’s perspective.
Later this summer, that conversation will focus on nonhealing chronic wounds, and among those invited to participate is Dr. Daniel Rastein, Founder and Chief Executive Officer of CassdermaRx. For a company developing new approaches for difficult-to-heal wounds, the invitation represents an opportunity to contribute to a national discussion about the future of wound care and the role patient experience should play in shaping new therapies.
One of the more interesting aspects of the FDA’s Patient-Focused Drug Development initiative is that it recognizes an important reality: clinical success and patient success are not always measured in exactly the same way.
For physicians and researchers, wound closure may be a primary clinical endpoint. For patients, success can also mean being able to sleep through the night, walking without pain, reducing the number of dressing changes, avoiding infection, or simply returning to everyday activities with greater independence. Those perspectives don’t replace traditional clinical measurements, but they do provide important context as new therapies move through development.
That is one reason Dr. Rastein’s invitation is significant.
As Founder and CEO of CassdermaRx, he has been involved in advancing a wound care technology designed to support healing in chronic and difficult-to-treat wounds. The company’s investigational platform continues progressing through clinical development, but participation in the FDA meeting is less about a specific product and more about contributing to a broader conversation taking place across healthcare.
Why This Matters to PFD
At PFD, we’ve always believed that meaningful healthcare innovation extends beyond the science itself. It also depends on understanding the people those innovations are intended to serve.
That is one reason Dr. Rastein’s invitation stands out. The FDA’s Patient-Focused Drug Development meeting represents an opportunity to bring together patients, caregivers, clinicians, researchers, and industry leaders to discuss what meaningful progress in wound care should actually look like. Those conversations help ensure that future therapies are evaluated not only by clinical measurements, but also by the real-world experiences of the people living with these conditions.
Supporting conversations like these reflects PFD’s broader commitment to healthcare solutions that place patients at the center of innovation. We believe the strongest advances in medicine occur when scientific research, clinical expertise, and patient perspectives work together toward the same goal: improving outcomes that truly matter.